AN2 Therapeutics, Inc.

31 articles about AN2 Therapeutics, Inc.

• AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

  3/28/2024

  AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.

• AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

  2/12/2024

  AN2 Therapeutics, Inc. (Nasdaq: ANTX) today announced the company’s decision to voluntarily pause Phase 3 enrollment in the seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.

• AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

  1/30/2024

  AN2 Therapeutics, Inc. (Nasdaq: ANTX) today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.

• AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

  11/9/2023

  AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023.

• AN2 Therapeutics to Present at Upcoming November 2023 Investor Conferences

  11/6/2023

  AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, announced that company management will participate in two upcoming investor conferences in November.

• AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

  10/18/2023

  AN2 Therapeutics, Inc. today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease.

• AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

  10/11/2023

  AN2 Therapeutics, Inc. announced two oral presentations and three poster presentations at the Infectious Disease Society of America IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts.

• AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

  9/26/2023

  AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria.

• AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

  9/13/2023

  AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease.

• AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

  8/16/2023

  AN2 Therapeutics, Inc. announced the pricing of an underwritten offering of 7,777,778 shares of its common stock.

• AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

  8/10/2023

  AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023.

• AN2 Therapeutics to Present at Jefferies 2023 Healthcare Conference

  5/25/2023

  AN2 Therapeutics, Inc. announced that Eric Easom, Co-Founder, President and CEO, will present at the Jefferies Healthcare Conference.

• AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

  5/11/2023

  AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2023.

• AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

  5/1/2023

  AN2 Therapeutics, Inc. today announced that Eric Easom, Co-Founder, President and CEO, will present at the JMP Securities Life Sciences Conference.

• AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

  3/29/2023

  AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.

• AN2 Therapeutics to Participate in Upcoming Investor Conferences

  2/28/2023

  AN2 Therapeutics, Inc. today announced that company management will participate in two upcoming investor conferences in March.

• AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

  1/31/2023

  AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference.

• AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

  11/9/2022

  AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2022.

• AN2 Therapeutics to Present at Upcoming November 2022 Investor Conferences

  11/2/2022

  AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, announced that company management will participate in two upcoming investor conferences in November.

• AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

  10/19/2022

  AN2 Therapeutics, Inc. (Nasdaq: ANTX) today announced one oral presentation and nine data poster presentations at the Infectious Disease Society of American (IDSA) IDWeek 2022 Conference from October 19-24, 2022 in Washington D.C. highlighting new data for epetraborole.